Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- 3 Dreamy Small-Cap Stocks
- Inside the Crash in Japan ETFs
- Correction or Summer Range Trade?
- Hitting Home Runs & Grand Slams, Not Loud Outs
- Hedge Your Portfolio with the Equity Bear ETF
- Machinery Industry Stock Outlook - May 2013
- Determining Correct Position Size with Options
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- AWS 5/24: Making Sense of Data & Taper Talk
- PFP 5/24: America vs. the Rest of the World
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/24/2013
| Company Name | Symbol | %Change |
|---|---|---|
| GENTIUM SPA | GENT | 2.47% |
| MENTOR GRAPH | MENT | 2.10% |
| INFORMATION | III | 2.09% |
| AMER NATL BK | AMNB | 1.99% |
| BARRETT BUSI | BBSI | 1.93% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We recently reiterated our Neutral recommendation on Quest Diagnostics (DGX - Analyst Report), the leading providers of commercial laboratory services in North America. While we hold a favorable view regarding the company’s organizational restructuring and efforts to align its assets with core strategies in order to restore growth, concerns linger around the overall soft industry trends leading to low volume growth for the company. The stock currently carries a Zacks Rank #4 (Sell).
Why at Neutral?
Pressure on volume owing to the difficult macroeconomic situation and pricing constitute the primary risk for Quest Diagnostics. In the last reported quarter, volume (measured by the number of requisitions) inched down 1.1% leading the company to lower its fiscal 2012 revenue guidance. We are concerned with the weak volume growth over the last few quarters and expect this low level of employment and slow growth of commercially insured lives to continuously impact the company’s overall growth until the economy rebounds.
However, over the past several years, Quest Diagnostics has been making efforts to align its assets with core strategies. The latest among these are the divestment of its OralDNA Labs business to refocus its resources to core diagnostic information services and the acquisition of UMass outreach labs to create the company’s planned 'lab of the future' . We hold a favorable view regarding the company’s organizational restructuring in order to restore growth. We also appreciate the company’s current focus on gene-based, esoteric testing, which has immense potential.
Over the past 30 days, none of the 15 firms covering the stock made any estimate revision for the current fiscal implying that they still hold similar views on the stock.
Other Stocks to Consider
While we prefer to remain on the sidelines on Quest Diagnostics, other medical device stocks worth a look are Derma Science Inc. (DSCI - Snapshot Report) and Nxstage Medical Inc. (NXTM - Snapshot Report). Both the stocks carry a Zacks Rank #1 (Strong Buy).
Read the full Analyst Report on DGX
Read the full Snapshot Report on NXTM
Read the full Snapshot Report on DSCI